Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled. https://hubs.li/Q030m_sr0
BioSpace
Internet News
West Des Moines, Iowa 126,696 followers
The leading source for biopharma news and jobs. Connecting industry pioneers with talented professionals.
About us
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
- Website
-
http://www.biospace.com/
External link for BioSpace
- Industry
- Internet News
- Company size
- 11-50 employees
- Headquarters
- West Des Moines, Iowa
- Type
- Privately Held
- Founded
- 1985
- Specialties
- biotech jobs, pharma jobs, biotech news, pharma news, and life sciences news
Locations
-
Primary
Get directions
3001 Westown Pkwy
#101
West Des Moines, Iowa 50266, US
Employees at BioSpace
-
Dr. D. Martin Alexander Gershon, MD, JD, MPH
AI & Digital Health Innovation Keynote•Linkedin “Top Voice” Venture Capital, Entrepreneurship, & Fundraising•Techstars Sr EIR•Goldman…
-
Angela Gabriel
Content Manager (Life Sciences Careers) at BioSpace
-
Lori Ellis
Market Intelligence Advisor | Moderator | Professional Speaker
-
Heather McKenzie
Senior Editor at BioSpace
Updates
-
Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that Tryngolza’s regulatory triumph will not be a significant positive for Ionis. Instead, the firm is focusing on olezarsen’s readout in severe hypertriglyceridemia, a much larger market. https://hubs.li/Q030lyP50
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome
biospace.com
-
Zealand’s GLP-2 drug shot down while Xcovery's Ensacove wins first approval https://hubs.li/Q030ltcf0
FDA Tracker: Zealand’s GLP-2 Drug Rejected While Xcovery Wins First Approval, Targets NSCLC
-
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s prior projections for the therapy. Meanwhile, Eli Lilly’s stock rose on the news. https://hubs.li/Q030lzPj0
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
-
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the third quarter. https://hubs.li/Q030ltrb0
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
-
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis. https://hubs.li/Q030lx6d0
Phase III MASH Miss Sends Galectin Stock Tumbling
-
After a couple months of uncertainty, the FDA has told compounding pharmacies that they have 60 to 90 days before the agency will enforce rules to stop their production of GLP-1s. #drugshortages #GLP1 #biospace https://hubs.li/Q030d0C20
FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period
biospace.com
-
BioArctic received $100 million upfront with another $1.25 billion in potential milestone payments on the line for two pyroglutamate-amyloid-beta antibodies. #alzheimers #pharma #biospace https://hubs.li/Q030d0VK0
BMS Taps Eisai’s Alzheimer’s Partner in Massive $1.35B Biobucks Deal
biospace.com
-
The closures follow Novartis's acquisition of MorphyoSys earlier this year. #layoffs #biopharma #biospace https://hubs.li/Q030ckKV0
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
-
The report comes just two days after Novartis announced its own Parkinson’s drug failure. #parkinsons #pharma #biospace https://hubs.li/Q030bN1B0
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
biospace.com